Journal article icon

Journal article

Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.

Abstract:

Conventional high-grade osteosarcoma is the most common primary bone malignancy. Although altered expression of the p53 inhibitor HDMX (Mdmx/Mdm4) is associated with cancer risk, progression, and outcome in other tumor types, little is known about its role in osteosarcoma. High expression of the Hdmx splice variant HDMX-S relative to the full-length transcript (the HDMX-S/HDMX-FL ratio) correlates with reduced HDMX protein expression, faster progression, and poorer survival in several cancers...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Grawenda, AM More by this author
Kuijjer, ML More by this author
Teunisse, AF More by this author
Expand authors...
Journal:
Cancer research
Volume:
72
Issue:
16
Pages:
4074-4084
Publication date:
2012-08-05
DOI:
EISSN:
1538-7445
ISSN:
0008-5472
URN:
uuid:d7b828f3-e344-4b9e-b057-a888aa49b9b4
Source identifiers:
339847
Local pid:
pubs:339847

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP